期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
特发性下丘脑综合征:回顾性研究和文献回顾
1
作者 Reynaud R. Lêger J. +1 位作者 Polak M. 郭战宏 《世界核心医学期刊文摘(儿科学分册)》 2005年第10期36-37,共2页
Hypothalamic obesity is usually induced by tumoral or genetic alterations such as craniopharyngioma or Prader-Willi syndrome, respectively. However, few case s have been reported without recognized etiology, this synd... Hypothalamic obesity is usually induced by tumoral or genetic alterations such as craniopharyngioma or Prader-Willi syndrome, respectively. However, few case s have been reported without recognized etiology, this syndrome is also called idiopathic hypothalamic syndrome. Objectives. -To improve definition a nd frequency of complications associated with this syndrome. Population and Meth ods. -A retrospective cohort study was performed in French endocrine paediatric departments and was associated with a literature review. Results. -We report f ive cases of idiopathic hypothalamic syndrome. This syndrome is correlated with a high mortality (one of our five cases, 25%in the literature) by neurovegetati ve dysfunction (breathing or thermal alteration). Obesity began before six years old because of compulsive eating and resulted in social behaviour disorders. Ab normal endocrine secretions were characterized by early hyperprolactinemia, perm anent but later somatotrope deficiency and 80%of thyreotrope deficiency. Pubert y abnormalities included hypogonadotropic hypogonadism as well as precocious (on e of our cases, three cases including literature) or normal puberty. Neurogenic hypernatremia and water and electrolytic disorders were also responsible of acut e neurological alterations. Conclusion. -This largest study ever reported of id iopathic hypothalamic syndrome emphasizes the need of amultidisciplinary coordin ation to provide the best care of these patients. 展开更多
关键词 下丘脑综合征 文献回顾 普-威综合征 下丘脑性肥胖 行为障碍 促生长激素 内分泌科 性腺功能低下 促甲状腺素 颅咽管瘤
下载PDF
FDA批准修改生长激素混悬液安全标示
2
《世界临床药物》 CAS 2005年第2期68-68,共1页
2004年10月,FDA批准修改注射用生长激素混悬液(somatropin,Nutropin)的安全标示:不宜用于存在严重肥胖或严重呼吸功能缺陷的普-威综合征(Prader-Willi syndrome)患者。本品仅用于确诊为有生长激素缺乏症(GHD)的遗传型普-威综合征儿... 2004年10月,FDA批准修改注射用生长激素混悬液(somatropin,Nutropin)的安全标示:不宜用于存在严重肥胖或严重呼吸功能缺陷的普-威综合征(Prader-Willi syndrome)患者。本品仅用于确诊为有生长激素缺乏症(GHD)的遗传型普-威综合征儿童患者的长期治疗。本品由Genentech公司生产。 展开更多
关键词 FDA 修改 生长激素混悬液 安全标示 普-威综合征 肥胖 呼吸功能缺陷 禁忌症 儿童
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部